Improvement in fatty acid utilization in relation to a change in left ventricular hypertrophy in spontaneously hypertensive rats.
Improvement in fatty acid utilization in relation to a change in left ventricular hypertrophy in spontaneously hypertensive rats.
复制标题
自发性高血压大鼠中脂肪酸利用的改善与左心室肥厚的变化有关。
DOI：
10.1253/jcj.64.117
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
A. Kitabatake
中科院分区：
文献类型：
--
作者：
T. Ono;T. Kohya;E. Tsukamoto;T. Mochizuki;K. Itoh;Y. Itoh;F. Tomita;N. Tamaki;A. Kitabatake
尽管据报道，心肌肥厚会损害脂肪酸代谢，但目前尚不清楚降压药物是否与改善脂肪酸代谢有关。为了评价降压药物对脂肪酸代谢和心肌血流的影响，测定了3组大鼠(1)自发性高血压大鼠(SHR-N)、(2)卡托普利慢性治疗组(SHR-C)和(3)肼安定慢性治疗组(SHR-H)对~(125)I-15-(对-碘苯基)-3-(R，S)-甲基十五烷酸(BMIPP)和~(201)Tl的同时摄取。从12周龄开始，分别给予卡托普利和肼丙嗪治疗3周。同时静脉注射BMIPP和TL 10min后取出心脏，测量~(125)I和~(201)Tl计数，计算摄取比。SHR-N组的收缩压(SBP)为222+/-10 mm Hg，而SHR-C组和SHR-H组的SBP显著降低(分别为156+/-11和158+/-10 mm Hg)(P均<0.01)。SHR-C组心脏/体重比(2.48+/-0.09)显著低于SHR-N组(2.74+/-0.11)(p<；0.05)。然而，SHR-N和SHR-H的心脏/体重比(2.65+/-0.09)无显著差异。SHR-C组BMIPP摄取/TL摄取比值(BMIPP/TL)(0.71+/-0.13)显著高于SHR-N组(0.50+/-0.09)(p<；0.05)。而SHR-H的BMIPP/TL(0.53+/-0.09)与SHR-N相似。这些结果提示卡托普利可改善自发性高血压大鼠肥厚心肌的脂肪酸代谢。随着左心室肥厚的消退，代谢改变可能改善，但不受单纯降压的影响。
Although fatty acid metabolism is reportedly impaired in myocardial hypertrophy, it is unclear whether the antihypertensive drugs are associated with improved fatty acid metabolism. In order to evaluate the effects of antihypertensive drugs on fatty acid metabolism and myocardial perfusion, the simultaneous uptake of iodine-125(125I)-15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) and thallium-201 (Tl) were measured in 3 groups of rats: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR chronically treated with captopril (SHR-C), and (3) SHR chronically treated with hydralazine (SHR-H). Captopril and hydralazine were administered to their respective groups for 3 weeks from 12 weeks of age. The hearts were removed 10 min after simultaneous intravenous injections of BMIPP and Tl and the 125I and 201Tl counts were measured to calculate the uptake ratio. The systolic blood pressure (SBP) in SHR-N was 222+/-10 mm Hg, whereas the SHR-C and SHR-H groups showed significant SBP reduction (156+/-11, and 158+/-10 mm Hg, respectively) (p<0.01 each). The heart/bodyweight ratio was significantly lower in SHR-C (2.48+/-0.09) than in SHR-N (2.74+/-0.11) (p<0.05). However, there was no significant difference in the heart/bodyweight ratio between SHR-N and SHR-H (2.65+/-0.09). The ratio of BMIPP uptake to Tl uptake (BMIPP/Tl) was significantly higher in SHR-C (0.71+/-0.13) than in SHR-N (0.50+/-0.09) (p<0.05). However, BMIPP/Tl in SHR-H (0.53+/-0.09) was similar to that in SHR-N. These results suggest that captopril improves fatty acid metabolism in the hypertrophied ventricle in SHR. The metabolic alterations may improve with left ventricular hypertrophy regression but are not effected by the reduction of blood pressure only.